A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

NCT02334748 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Juvenile Idiopathic Arthritis
Hereditary Periodic Fevers

Interventions

DRUG: canakinumab

Sponsor

Novartis Pharmaceuticals